
In the year 2021, hearing aid manufacturer GN Hearing was meant to launch two new products. However, a failure from the company’s research and development department delayed the plans, causing both a guidance downgrade to ”around 16 percent” from earlier ”more than 25 percent” and the immediate departure of the man in charge of the team.
”We’ve matched expectations in our revised guidance. That said, I would have liked to see some things perform better in 2021. For example our R&D pipeline, and we have of course also faced headwinds from the pandemic,” CEO of GN Hearing Gitte Aabo tells MedWatch in connection with the company’s 2021 financial report on Thursday.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app